These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 19223878)

  • 61. Flavanol-rich cocoa a promising new dietary intervention to reduce cardiovascular risk in type 2 diabetes?
    Campia U; Panza JA
    J Am Coll Cardiol; 2008 Jun; 51(22):2150-2. PubMed ID: 18510962
    [No Abstract]   [Full Text] [Related]  

  • 62. Impact of glycemic treatment choices on cardiovascular complications in type 2 diabetes.
    Weiss IA; Valiquette G; Schwarcz MD
    Cardiol Rev; 2009; 17(4):165-75. PubMed ID: 19525678
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Exercise training for type 2 diabetes mellitus: impact on cardiovascular risk: a scientific statement from the American Heart Association.
    Marwick TH; Hordern MD; Miller T; Chyun DA; Bertoni AG; Blumenthal RS; Philippides G; Rocchini A; ; ; ; ;
    Circulation; 2009 Jun; 119(25):3244-62. PubMed ID: 19506108
    [No Abstract]   [Full Text] [Related]  

  • 64. Basing approval of drugs for type 2 diabetes on real world outcomes.
    McGovern A; Hinchliffe R; Munro N; de Lusignan S
    BMJ; 2015 Nov; 351():h5829. PubMed ID: 26530057
    [No Abstract]   [Full Text] [Related]  

  • 65. FDA: antimicrobial risk assessment model near completion.
    Nolen S
    J Am Vet Med Assoc; 1999 Jun; 214(12):1743. PubMed ID: 10382011
    [No Abstract]   [Full Text] [Related]  

  • 66. Diabetes & depression. A twin threat to women's hearts. Research profile. Julie Ann Wagner, PhD.
    D'Arrigo T
    Diabetes Forecast; 2007 May; 60(6):59-60. PubMed ID: 17566228
    [No Abstract]   [Full Text] [Related]  

  • 67. Avandia update. Committee urges caution on heart risks.
    D'Arrigo T
    Diabetes Forecast; 2007 Sep; 60(10):18. PubMed ID: 17941141
    [No Abstract]   [Full Text] [Related]  

  • 68. FDA revives compounding advisory committee.
    Traynor K
    Am J Health Syst Pharm; 2015 Apr; 72(8):598-9. PubMed ID: 25825176
    [No Abstract]   [Full Text] [Related]  

  • 69. Glycemic management of type 2 diabetes: how tight is right and how to get there.
    Nathan DM
    Arch Intern Med; 2008 Oct; 168(19):2064-6. PubMed ID: 18955633
    [No Abstract]   [Full Text] [Related]  

  • 70. Impact of FDA-Required Cardiovascular Outcome Trials on Type 2 Diabetes Clinical Study Initiation From 2008 to 2017.
    Kieffer CM; Robertson AS
    Ther Innov Regul Sci; 2020 May; 54(3):640-644. PubMed ID: 33301138
    [TBL] [Abstract][Full Text] [Related]  

  • 71. US guidance on formatting 510(k)s.
    Donawa M
    Med Device Technol; 2006 Mar; 17(2):27-9. PubMed ID: 16610716
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The need for reorientation toward cost-effective prediction: comments on 'Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond' by Pencina et al., Statistics in Medicine (DOI: 10.1002/sim.2929).
    Chi YY; Zhou XH
    Stat Med; 2008 Jan; 27(2):182-4. PubMed ID: 17712782
    [No Abstract]   [Full Text] [Related]  

  • 73. Where do our priorities lie?
    Hanauer SB
    Nat Clin Pract Gastroenterol Hepatol; 2007 Jul; 4(7):353. PubMed ID: 17607292
    [No Abstract]   [Full Text] [Related]  

  • 74. The need for reorientation toward cost-effective prediction: comments on 'Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond' by M. J. Pencina et al., Statistics in Medicine (DOI: 10.1002/sim.2929).
    Greenland S
    Stat Med; 2008 Jan; 27(2):199-206. PubMed ID: 17729377
    [No Abstract]   [Full Text] [Related]  

  • 75. Observations, predictions and decisions--assessing cardiovascular risk assessment.
    Hense HW
    Int J Epidemiol; 2004 Apr; 33(2):235-9. PubMed ID: 15082618
    [No Abstract]   [Full Text] [Related]  

  • 76. Comments on 'Evaluating the added predictive ability of a new marker' by M. Pencina, R. D'Agostino, R. D'Agostino Jr, R. Vasan, Statistics in Medicine (DOI: 10.1002/sim.2929).
    Kraemer HC
    Stat Med; 2008 Jan; 27(2):196-8. PubMed ID: 18041049
    [No Abstract]   [Full Text] [Related]  

  • 77. A new crystal ball.
    Harv Heart Lett; 2008 May; 18(9):5. PubMed ID: 18655305
    [No Abstract]   [Full Text] [Related]  

  • 78. Type 2 drug up risk of fractures.
    Ruder K
    Diabetes Forecast; 2007 May; 60(6):29-30. PubMed ID: 17566220
    [No Abstract]   [Full Text] [Related]  

  • 79. Under the conditions of intended use - New developments in the FEMA GRAS program and the safety assessment of flavor ingredients.
    Hallagan JB; Hall RL
    Food Chem Toxicol; 2009 Feb; 47(2):267-78. PubMed ID: 19041920
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Are synthetic hypoglycemic agents dangerous?].
    Dérot M
    Journ Annu Diabetol Hotel Dieu; 1971 May; 12(0):253-5. PubMed ID: 5164714
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.